shadforth pharmaceutical company limited Company Information
Company Number
00143500
Website
www.shadforths.co.ukRegistered Address
unit 13 4 cromar way, chelmsford, essex, CM1 2GL
Industry
Dispensing chemist in specialised stores
Telephone
01245359722
Next Accounts Due
October 2024
Group Structure
View All
Shareholders
shadforth holdings limited 100%
shadforth pharmaceutical company limited Estimated Valuation
Pomanda estimates the enterprise value of SHADFORTH PHARMACEUTICAL COMPANY LIMITED at £3.3m based on a Turnover of £9.2m and 0.36x industry multiple (adjusted for size and gross margin).
shadforth pharmaceutical company limited Estimated Valuation
Pomanda estimates the enterprise value of SHADFORTH PHARMACEUTICAL COMPANY LIMITED at £0 based on an EBITDA of £-2.5m and a 5.31x industry multiple (adjusted for size and gross margin).
shadforth pharmaceutical company limited Estimated Valuation
Pomanda estimates the enterprise value of SHADFORTH PHARMACEUTICAL COMPANY LIMITED at £3.5m based on Net Assets of £1.4m and 2.48x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Shadforth Pharmaceutical Company Limited Overview
Shadforth Pharmaceutical Company Limited is a live company located in essex, CM1 2GL with a Companies House number of 00143500. It operates in the dispensing chemist in specialised stores sector, SIC Code 47730. Founded in April 1916, it's largest shareholder is shadforth holdings limited with a 100% stake. Shadforth Pharmaceutical Company Limited is a mature, mid sized company, Pomanda has estimated its turnover at £9.2m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Shadforth Pharmaceutical Company Limited Health Check
Pomanda's financial health check has awarded Shadforth Pharmaceutical Company Limited a 4 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 4 areas for improvement. Company Health Check FAQs
4 Strong
4 Regular
4 Weak
Size
annual sales of £9.2m, make it in line with the average company (£11.1m)
- Shadforth Pharmaceutical Company Limited
£11.1m - Industry AVG
Growth
3 year (CAGR) sales growth of 7%, show it is growing at a faster rate (5.2%)
- Shadforth Pharmaceutical Company Limited
5.2% - Industry AVG
Production
with a gross margin of 32.3%, this company has a comparable cost of product (32.3%)
- Shadforth Pharmaceutical Company Limited
32.3% - Industry AVG
Profitability
an operating margin of -27.8% make it less profitable than the average company (5.1%)
- Shadforth Pharmaceutical Company Limited
5.1% - Industry AVG
Employees
with 122 employees, this is above the industry average (83)
122 - Shadforth Pharmaceutical Company Limited
83 - Industry AVG
Pay Structure
on an average salary of £21.8k, the company has an equivalent pay structure (£21.8k)
- Shadforth Pharmaceutical Company Limited
£21.8k - Industry AVG
Efficiency
resulting in sales per employee of £75.4k, this is less efficient (£128.8k)
- Shadforth Pharmaceutical Company Limited
£128.8k - Industry AVG
Debtor Days
it gets paid by customers after 31 days, this is near the average (29 days)
- Shadforth Pharmaceutical Company Limited
29 days - Industry AVG
Creditor Days
its suppliers are paid after 42 days, this is quicker than average (70 days)
- Shadforth Pharmaceutical Company Limited
70 days - Industry AVG
Stock Days
it holds stock equivalent to 39 days, this is more than average (31 days)
- Shadforth Pharmaceutical Company Limited
31 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 22 weeks, this is more cash available to meet short term requirements (17 weeks)
22 weeks - Shadforth Pharmaceutical Company Limited
17 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 36.3%, this is a lower level of debt than the average (63.7%)
36.3% - Shadforth Pharmaceutical Company Limited
63.7% - Industry AVG
SHADFORTH PHARMACEUTICAL COMPANY LIMITED financials
Shadforth Pharmaceutical Company Limited's latest turnover from January 2023 is estimated at £9.2 million and the company has net assets of £1.4 million. According to their latest financial statements, Shadforth Pharmaceutical Company Limited has 122 employees and maintains cash reserves of £332.8 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
Jan 2023 | Jan 2022 | Jan 2021 | Jan 2020 | Jan 2019 | Jan 2018 | Jan 2017 | Jan 2016 | Jan 2015 | Jan 2014 | Jan 2013 | Jan 2012 | Jan 2011 | Jan 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Turnover | 8,765,158 | 8,710,045 | 8,634,205 | 8,428,031 | 8,467,379 | 8,738,590 | 8,960,643 | 9,330,560 | 9,068,554 | |||||
Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||
Cost Of Sales | 6,350,381 | 6,198,662 | 6,007,542 | 6,043,420 | 6,000,838 | 6,156,821 | 6,603,439 | |||||||
Gross Profit | 2,414,777 | 2,511,383 | 2,626,663 | 2,384,611 | 2,466,541 | 2,581,769 | 2,357,204 | |||||||
Admin Expenses | 2,309,020 | 2,338,784 | 2,371,806 | 2,317,158 | 2,307,378 | 2,260,112 | 2,152,219 | |||||||
Operating Profit | 105,757 | 172,599 | 254,857 | 67,453 | 159,163 | 321,657 | 204,985 | 672,461 | 478,858 | |||||
Interest Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 122,000 | |||||
Interest Receivable | 690 | 4,311 | 5,152 | 5,428 | 5,104 | 8,780 | 34,741 | 34,662 | 35,972 | |||||
Pre-Tax Profit | 106,447 | 176,910 | 260,009 | 72,881 | 164,267 | 330,437 | 226,640 | 707,123 | 392,830 | |||||
Tax | -19,865 | -35,906 | -50,390 | -6,740 | -39,710 | -63,302 | -51,986 | -186,964 | -126,262 | |||||
Profit After Tax | 86,582 | 141,004 | 209,619 | 66,141 | 124,557 | 267,135 | 174,654 | 520,159 | 266,568 | |||||
Dividends Paid | 100,800 | 100,800 | 100,800 | 162,000 | 170,300 | 157,200 | 188,954 | 220,800 | 146,160 | |||||
Retained Profit | -14,218 | 40,204 | 108,819 | -95,859 | -45,743 | 109,935 | -14,300 | 299,359 | 120,408 | |||||
Employee Costs | 2,071,577 | 2,055,267 | 2,079,155 | 1,969,430 | 1,969,620 | 1,933,013 | 1,828,794 | 1,684,076 | 1,663,362 | |||||
Number Of Employees | 122 | 122 | 120 | 121 | 113 | 111 | 111 | 113 | 113 | 113 | 111 | 104 | 100 | 96 |
EBITDA* | 147,235 | 220,545 | 307,314 | 114,796 | 211,013 | 350,956 | 231,255 | 687,190 | 489,199 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
Jan 2023 | Jan 2022 | Jan 2021 | Jan 2020 | Jan 2019 | Jan 2018 | Jan 2017 | Jan 2016 | Jan 2015 | Jan 2014 | Jan 2013 | Jan 2012 | Jan 2011 | Jan 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tangible Assets | 162,465 | 2,272,952 | 1,743,588 | 1,718,715 | 1,320,045 | 1,312,369 | 1,307,426 | 1,330,051 | 1,331,985 | 1,316,565 | 1,123,410 | 747,499 | 657,374 | 645,070 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Fixed Assets | 162,465 | 2,272,952 | 1,743,588 | 1,718,715 | 1,320,045 | 1,312,369 | 1,307,426 | 1,330,051 | 1,331,985 | 1,316,565 | 1,123,410 | 747,499 | 657,374 | 645,070 |
Stock & work in progress | 680,027 | 589,059 | 537,100 | 567,909 | 565,233 | 547,228 | 493,236 | 531,608 | 549,116 | 534,406 | 591,173 | 596,089 | 602,089 | 577,492 |
Trade Debtors | 785,241 | 622,115 | 1,447,518 | 699,263 | 1,198,025 | 1,300,960 | 1,252,611 | 1,314,996 | 627,308 | 636,095 | 1,370,731 | 1,468,427 | 1,497,992 | 806,260 |
Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Misc Debtors | 284,262 | 209,593 | 189,608 | 211,140 | 207,068 | 194,276 | 194,327 | 185,580 | 205,920 | 471,236 | 242,280 | 206,462 | 198,934 | 177,109 |
Cash | 332,752 | 1,398,273 | 1,181,219 | 1,264,077 | 1,340,480 | 1,519,426 | 1,800,925 | 1,650,327 | 2,320,128 | 2,435,835 | 2,060,683 | 2,173,175 | 1,440,759 | 1,355,724 |
misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 997,813 | 997,813 |
total current assets | 2,082,282 | 2,819,040 | 3,355,445 | 2,742,389 | 3,310,806 | 3,561,890 | 3,741,099 | 3,682,511 | 3,702,472 | 4,077,572 | 4,264,867 | 4,444,153 | 4,737,587 | 3,914,398 |
total assets | 2,244,747 | 5,091,992 | 5,099,033 | 4,461,104 | 4,630,851 | 4,874,259 | 5,048,525 | 5,012,562 | 5,034,457 | 5,394,137 | 5,388,277 | 5,191,652 | 5,394,961 | 4,559,468 |
Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Creditors | 725,249 | 880,357 | 854,348 | 847,136 | 952,246 | 899,473 | 897,036 | 898,572 | 995,828 | 1,181,411 | 1,084,932 | 1,041,202 | 1,122,268 | 629,425 |
Group/Directors Accounts | 3,167 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other current liabilities | 53,288 | 227,963 | 536,820 | 163,381 | 144,355 | 307,295 | 468,780 | 466,985 | 500,443 | 575,281 | 647,357 | 602,147 | 727,685 | 687,366 |
total current liabilities | 781,704 | 1,108,320 | 1,391,168 | 1,010,517 | 1,096,601 | 1,206,768 | 1,365,816 | 1,365,557 | 1,496,271 | 1,756,692 | 1,732,289 | 1,643,349 | 1,849,953 | 1,316,791 |
loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 500 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other liabilities | 0 | 0 | 0 | 0 | 17,719 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
provisions | 34,000 | 28,000 | 33,000 | 39,000 | 37,000 | 42,500 | 43,500 | 47,500 | 47,500 | 50,900 | 23,700 | 25,950 | 8,355 | 5,383 |
total long term liabilities | 34,000 | 28,000 | 33,000 | 39,000 | 54,719 | 42,500 | 43,500 | 47,500 | 47,500 | 50,900 | 23,700 | 25,950 | 8,355 | 5,883 |
total liabilities | 815,704 | 1,136,320 | 1,424,168 | 1,049,517 | 1,151,320 | 1,249,268 | 1,409,316 | 1,413,057 | 1,543,771 | 1,807,592 | 1,755,989 | 1,669,299 | 1,858,308 | 1,322,674 |
net assets | 1,429,043 | 3,955,672 | 3,674,865 | 3,411,587 | 3,479,531 | 3,624,991 | 3,639,209 | 3,599,505 | 3,490,686 | 3,586,545 | 3,632,288 | 3,522,353 | 3,536,653 | 3,236,794 |
total shareholders funds | 1,429,043 | 3,955,672 | 3,674,865 | 3,411,587 | 3,479,531 | 3,624,991 | 3,639,209 | 3,599,505 | 3,490,686 | 3,586,545 | 3,632,288 | 3,522,353 | 3,536,653 | 3,236,794 |
Jan 2023 | Jan 2022 | Jan 2021 | Jan 2020 | Jan 2019 | Jan 2018 | Jan 2017 | Jan 2016 | Jan 2015 | Jan 2014 | Jan 2013 | Jan 2012 | Jan 2011 | Jan 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Activities | ||||||||||||||
Operating Profit | 105,757 | 172,599 | 254,857 | 67,453 | 159,163 | 321,657 | 204,985 | 672,461 | 478,858 | |||||
Depreciation | 33,739 | 35,437 | 39,260 | 47,540 | 40,019 | 41,478 | 47,946 | 52,457 | 47,343 | 51,850 | 29,299 | 26,270 | 14,729 | 10,341 |
Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax | -19,865 | -35,906 | -50,390 | -6,740 | -39,710 | -63,302 | -51,986 | -186,964 | -126,262 | |||||
Stock | 90,968 | 51,959 | -30,809 | 2,676 | 18,005 | 53,992 | -38,372 | -17,508 | 14,710 | -56,767 | -4,916 | -6,000 | 24,597 | 577,492 |
Debtors | 237,795 | -805,418 | 726,723 | -494,690 | -90,143 | 48,298 | -53,638 | 667,348 | -274,103 | -505,680 | -61,878 | -22,037 | 713,557 | 983,369 |
Creditors | -155,108 | 26,009 | 7,212 | -105,110 | 52,773 | 2,437 | -1,536 | -97,256 | -185,583 | 96,479 | 43,730 | -81,066 | 492,843 | 629,425 |
Accruals and Deferred Income | -174,675 | -308,857 | 373,439 | 19,026 | -162,940 | -161,485 | 1,795 | -33,458 | -74,838 | -72,076 | 45,210 | -125,538 | 40,319 | 687,366 |
Deferred Taxes & Provisions | 6,000 | -5,000 | -6,000 | 2,000 | -5,500 | -1,000 | -4,000 | 0 | -3,400 | 27,200 | -2,250 | 17,595 | 2,972 | 5,383 |
Cash flow from operations | -134,968 | 272,908 | -523,630 | 103,628 | 785,353 | 441,138 | 18,297 | 298,206 | 124,250 | |||||
Investing Activities | ||||||||||||||
capital expenditure | -48,043 | -25,321 | -49,687 | -62,964 | -245,005 | -405,210 | 868,332 | -25,405 | -16,205 | |||||
Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
cash flow from investments | -48,043 | -25,321 | -49,687 | -62,964 | -245,005 | -405,210 | 868,332 | -25,405 | -16,205 | |||||
Financing Activities | ||||||||||||||
Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Group/Directors Accounts | 3,167 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -500 | 500 |
Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other long term liabilities | 0 | 0 | 0 | -17,719 | 17,719 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
share issue | ||||||||||||||
interest | 690 | 4,311 | 5,152 | 5,428 | 5,104 | 8,780 | 34,741 | 34,662 | -86,028 | |||||
cash flow from financing | 690 | 3,811 | 5,152 | 5,428 | 5,104 | 8,780 | 34,741 | 34,662 | 3,030,858 | |||||
cash and cash equivalents | ||||||||||||||
cash | -1,065,521 | 217,054 | -82,858 | -76,403 | -178,946 | -281,499 | 150,598 | -669,801 | -115,707 | 375,152 | -112,492 | 732,416 | 85,035 | 1,355,724 |
overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
change in cash | -1,065,521 | 217,054 | -82,858 | -76,403 | -178,946 | -281,499 | 150,598 | -669,801 | -115,707 | 375,152 | -112,492 | 732,416 | 85,035 | 1,355,724 |
shadforth pharmaceutical company limited Credit Report and Business Information
Shadforth Pharmaceutical Company Limited Competitor Analysis
Perform a competitor analysis for shadforth pharmaceutical company limited by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other mid companies, companies in CM1 area or any other competitors across 12 key performance metrics.
shadforth pharmaceutical company limited Ownership
SHADFORTH PHARMACEUTICAL COMPANY LIMITED group structure
Shadforth Pharmaceutical Company Limited has no subsidiary companies.
Ultimate parent company
1 parent
SHADFORTH PHARMACEUTICAL COMPANY LIMITED
00143500
shadforth pharmaceutical company limited directors
Shadforth Pharmaceutical Company Limited currently has 2 directors. The longest serving directors include Mr Richard Shadforth (Oct 1991) and Mr Thomas Shadforth (Jan 2012).
officer | country | age | start | end | role |
---|---|---|---|---|---|
Mr Richard Shadforth | United Kingdom | 83 years | Oct 1991 | - | Director |
Mr Thomas Shadforth | United Kingdom | 52 years | Jan 2012 | - | Director |
P&L
January 2023turnover
9.2m
+11%
operating profit
-2.6m
0%
gross margin
32.3%
+0.01%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
January 2023net assets
1.4m
-0.64%
total assets
2.2m
-0.56%
cash
332.8k
-0.76%
net assets
Total assets minus all liabilities
shadforth pharmaceutical company limited company details
company number
00143500
Type
Private limited with Share Capital
industry
47730 - Dispensing chemist in specialised stores
incorporation date
April 1916
age
108
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
January 2023
previous names
N/A
accountant
-
auditor
-
address
unit 13 4 cromar way, chelmsford, essex, CM1 2GL
Bank
BARCLAYS BANK PLC
Legal Advisor
-
shadforth pharmaceutical company limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 4 charges/mortgages relating to shadforth pharmaceutical company limited. Currently there are 1 open charges and 3 have been satisfied in the past.
shadforth pharmaceutical company limited Companies House Filings - See Documents
date | description | view/download |
---|